NYSE · MRK · Drug Manufacturers - General
Merck (MRK) stock analysis
- MRK lost 0.7% over the past month versus 0.0% for the S&P 500, ranking 326th of 497 S&P 500 stocks.
- Over 12 months it returned +76.4%, 60.6 points ahead of the S&P 500, and trades 4.2% below its 52-week high.
- In the last 30 days 1 analyst raised earnings estimates and 10 cut; forward EPS moved −3.0% (−4.1% over 90 days).
- It sits in the Large pharma segment of the Healthcare Value Chain, where the 1-month median return is −0.7%.
- The daily chart reads Intermediate uptrend · Trend pullback (since Oct 21, 2026).
One-year price with 50- and 200-day averages
Performance vs the market
Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.
Chart structure
Read by our daily-bar structure engine from swing highs, swing lows and moving averages.
Holding since Oct 21, 2026
- Close above EMA20 above EMA50
- EMA50 rose over the last ten sessions
- Confirmed swing highs and lows are rising
63 occurrences in 10 years. The median move over the next 20 sessions was +0.4%, positive 56% of the time, against +0.9% for any day in the same period.
Analyst earnings revisions
Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.
25 analysts cover the stock
Where it sits in the supply chain
Healthcare Value Chain · Drugs & devices
Oncology, immunology and vaccines, facing patent expiries and US price negotiation; policy news often moves the group together.
Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps
Risk profile
Themes
- Gene/Cell Therapy3M rank 27 / 99
Track this stock every day
Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.